Edition:
United Kingdom

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.66USD
18 Dec 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.66
Open
$1.69
Day's High
$1.72
Day's Low
$1.63
Volume
238,462
Avg. Vol
709,160
52-wk High
$4.05
52-wk Low
$0.98

Latest Key Developments (Source: Significant Developments)

MannKind Corp Reports Q3 Loss Per Share $0.16
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - MannKind Corp ::MANNKIND CORPORATION REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.FOR Q3 OF 2018, AFREZZA NET REVENUE WAS $4.4 MILLION, AN INCREASE OF 121%.  Full Article

Mannkind Corp - CO, UNIT Entered Into Tenth Amendment To Facility Agreement Dated July 1, 2013
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - MannKind Corp ::MANNKIND CORP - ON SEPT 26, CO, UNIT ENTERED INTO TENTH AMENDMENT TO FACILITY AGREEMENT DATED JULY 1, 2013 - SEC FILING.  Full Article

United Therapeutics And Mannkind Announce Collaboration For Pulmonary Hypertension Products
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - MannKind Corp ::UNITED THERAPEUTICS AND MANNKIND ANNOUNCE COLLABORATION FOR PULMONARY HYPERTENSION PRODUCTS.MANNKIND CORP - MANNKIND CORPORATION WILL RECEIVE AN UPFRONT PAYMENT OF $45 MILLION.MANNKIND CORP - MANNKIND WILL ALSO RECEIVE POTENTIAL MILESTONE PAYMENTS OF UP TO $50 MILLION.MANNKIND CORP - WILL BE ENTITLED TO RECEIVE LOW DOUBLE-DIGIT ROYALTIES ON NET SALES OF PRODUCT.MANNKIND - GRANTED UNITED THERAPEUTICS AN OPTION TO EXPAND LICENSE TO INCLUDE OTHER ACTIVE INGREDIENTS FOR TREATMENT OF PULMONARY HYPERTENSION.  Full Article

United Therapeutics And Mannkind Announce Collaboration For Pulmonary Hypertension Products
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - MannKind Corp ::UNITED THERAPEUTICS AND MANNKIND ANNOUNCE COLLABORATION FOR PULMONARY HYPERTENSION PRODUCTS.UNITED THERAPEUTICS CORP - EXCLUSIVE LICENSE AGREEMENT FOR TREPROSTINIL TECHNOSPHERE.UNITED THERAPEUTICS CORP - $95 MILLION IN UPFRONT AND MILESTONE PAYMENTS UNDER DEAL.UNITED THERAPEUTICS CORP - RESEARCH AGREEMENT FOR ADDITIONAL PRODUCTS FOR ADDITIONAL $10 MILLION.  Full Article

Tanner Pharma Group Signs Distribution Agreement With MannKind Corporation
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - MannKind Corp ::TANNER PHARMA GROUP SIGNS DISTRIBUTION AGREEMENT WITH MANNKIND CORPORATION.TANNER PHARMA GROUP - AGREEMENT NAMES CO AS DISTRIBUTOR OF AFREZZA INHALATION POWDER IN AREAS OUTSIDE OF U.S. WHERE PRODUCT IS NOT YET REGISTERED.  Full Article

Mannkind And Tanner Pharma Enter Into An Ex-U.S. Distribution Agreement For Afrezza®
Friday, 27 Jul 2018 

July 27 (Reuters) - MannKind Corp ::MANNKIND AND TANNER PHARMA GROUP ENTER INTO AN EX-U.S. DISTRIBUTION AGREEMENT FOR AFREZZA®.MANNKIND CORP - AGREEMENT NAMES TANNER AS A DISTRIBUTOR OF AFREZZA OUTSIDE OF UNITED STATES IN REGIONS PRODUCT IS NOT YET REGISTERED.MANNKIND CORP - DISTRIBUTION WILL BE MANAGED BY TANNERGAP, INC UNIT OF TANNER PHARMA GROUP.  Full Article

Mannkind Corp To Issue 2.25 Mln Shares In Exchange For Cancellation Of $5.0 Mln Principal Amount Of 2021 Notes
Friday, 25 May 2018 

May 25 (Reuters) - MannKind Corp ::MANNKIND CORP - TO ISSUE 2.25 MILLION SHARES IN EXCHANGE FOR CANCELLATION OF $5.0 MILLION PRINCIPAL AMOUNT OF 2021 NOTES.MANNKIND CORP - ENTERED INTO A EXCHANGE AGREEMENT WITH CERTAIN HOLDERS OF ITS OUTSTANDING 5.75% CONVERTIBLE SENIOR NOTES DUE 2021 - SEC FILING.  Full Article

MannKind Restructures $79.7 Mln Debt Obligation To The Mann Group
Monday, 12 Mar 2018 

March 12 (Reuters) - MannKind Corp ::MANNKIND RESTRUCTURES $79.7 MILLION DEBT OBLIGATION TO THE MANN GROUP AND REDUCES PRINCIPAL OWED TO DEERFIELD BY $6.3 MILLION.MANNKIND- MATURITY DATE OF REMAINING PRINCIPAL OF ABOUT $71.5 MILLION UNDER AMENDED PROMISSORY NOTE WITH MANN GROUP EXTENDED 18MONTHS TO JULY 1,2021.MANNKIND - ‍RESTRUCTURING OF CERTAIN OF DEBT OBLIGATIONS, REDUCING OUTSTANDING PRINCIPAL BY $14.5 MILLION ALONG WITH CORRESPONDING INTEREST EXPENSE​.MANNKIND- CO,MANN GROUP ENTERED INTO COMMON STOCK PURCHASE AGREEMENT UNDER WHICH MANN GROUP AGREED TO BUY 3 MILLION SHARES OF CO'S STOCK AT $2.72/SHARE.MANNKIND- MANN GROUP AGREED TO CANCEL $8.2 MILLION IN PRINCIPAL AMOUNT UNDER PROMISSORY NOTE DATED OCT 18, 2012.  Full Article

Mannkind Q3 loss per share $0.31
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Mannkind Corp ::Mannkind Corporation reports 2017 third quarter financial results.Q3 loss per share $0.31.  Full Article

Mannkind restructures near-term debt obligations
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Mannkind Corp ::Mannkind restructures near-term debt obligations.Mannkind Corp - ‍extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock​.Mannkind - ‍new 5.75 pct convertible senior subordinated exchange notes due 2021, common stock to be issued.Mannkind - ‍new 5.75 pct notes due 2021, common stock to be issued in exchange for existing convertible senior subordinated exchange notes due 2018​.Mannkind - ‍2021 notes will bear interest at rate of 5.75 pct per year on principal amount, payable semiannually​.Mannkind - ‍2021 notes will mature on october 23, 2021​.Mannkind - facility agreement amended to provide that deerfield may convert principal due into aggregate of up to 4 million shares of co's stock​.  Full Article